Literature DB >> 24390348

Landscape of genomic alterations in cervical carcinomas.

Akinyemi I Ojesina1, Lee Lichtenstein2, Samuel S Freeman3, Chandra Sekhar Pedamallu4, Ivan Imaz-Rosshandler5, Trevor J Pugh4, Andrew D Cherniack3, Lauren Ambrogio3, Kristian Cibulskis3, Bjørn Bertelsen6, Sandra Romero-Cordoba5, Victor Treviño7, Karla Vazquez-Santillan5, Alberto Salido Guadarrama5, Alexi A Wright8, Mara W Rosenberg3, Fujiko Duke9, Bethany Kaplan4, Rui Wang10, Elizabeth Nickerson3, Heather M Walline11, Michael S Lawrence3, Chip Stewart3, Scott L Carter3, Aaron McKenna3, Iram P Rodriguez-Sanchez12, Magali Espinosa-Castilla5, Kathrine Woie13, Line Bjorge14, Elisabeth Wik14, Mari K Halle14, Erling A Hoivik14, Camilla Krakstad14, Nayeli Belem Gabiño5, Gabriela Sofia Gómez-Macías12, Lezmes D Valdez-Chapa12, María Lourdes Garza-Rodríguez12, German Maytorena15, Jorge Vazquez15, Carlos Rodea15, Adrian Cravioto15, Maria L Cortes3, Heidi Greulich16, Christopher P Crum17, Donna S Neuberg18, Alfredo Hidalgo-Miranda5, Claudia Rangel Escareno19, Lars A Akslen20, Thomas E Carey21, Olav K Vintermyr20, Stacey B Gabriel3, Hugo A Barrera-Saldaña12, Jorge Melendez-Zajgla5, Gad Getz22, Helga B Salvesen23, Matthew Meyerson24.   

Abstract

Cervical cancer is responsible for 10-15% of cancer-related deaths in women worldwide. The aetiological role of infection with high-risk human papilloma viruses (HPVs) in cervical carcinomas is well established. Previous studies have also implicated somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS as well as several copy-number alterations in the pathogenesis of cervical carcinomas. Here we report whole-exome sequencing analysis of 115 cervical carcinoma-normal paired samples, transcriptome sequencing of 79 cases and whole-genome sequencing of 14 tumour-normal pairs. Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene (8%), inactivating mutations in the HLA-B gene (9%), and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), TP53 (5%) and ERBB2 (6%). We also observe somatic ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas. Squamous cell carcinomas have higher frequencies of somatic nucleotide substitutions occurring at cytosines preceded by thymines (Tp*C sites) than adenocarcinomas. Gene expression levels at HPV integration sites were statistically significantly higher in tumours with HPV integration compared with expression of the same genes in tumours without viral integration at the same site. These data demonstrate several recurrent genomic alterations in cervical carcinomas that suggest new strategies to combat this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24390348      PMCID: PMC4161954          DOI: 10.1038/nature12881

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  51 in total

1.  Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model.

Authors:  Kit I Tong; Yasutake Katoh; Hideki Kusunoki; Ken Itoh; Toshiyuki Tanaka; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

2.  High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.

Authors:  Heather M Walline; Chris Komarck; Jonathan B McHugh; Serena A Byrd; Matthew E Spector; Samantha J Hauff; Martin P Graham; Emily Bellile; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Douglas B Chepeha; Francis P Worden; Matthew H Stenmark; Avraham Eisbruch; Carol R Bradford; Thomas E Carey
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-12       Impact factor: 6.223

Review 3.  Mechanisms of MHC class I--restricted antigen processing.

Authors:  E Pamer; P Cresswell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation.

Authors:  Ramanathan Arvind; Hiroaki Shimamoto; Fumio Momose; Teruo Amagasa; Ken Omura; Nobuo Tsuchida
Journal:  Int J Oncol       Date:  2005-12       Impact factor: 5.650

5.  ErbB2 activation of ESX gene expression.

Authors:  Richard M Neve; Bauke Ylstra; Chuan-Hsiung Chang; Donna G Albertson; Christopher C Benz
Journal:  Oncogene       Date:  2002-05-30       Impact factor: 9.867

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 7.  The WD repeat: a common architecture for diverse functions.

Authors:  T F Smith; C Gaitatzes; K Saxena; E J Neer
Journal:  Trends Biochem Sci       Date:  1999-05       Impact factor: 13.807

8.  Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies.

Authors:  H Yang; K Yang; A Khafagi; Y Tang; T E Carey; A W Opipari; R Lieberman; P A Oeth; W Lancaster; H P Klinger; A O Kaseb; A Metwally; H Khaled; D M Kurnit
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

9.  Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours.

Authors:  T Crook; D Wrede; J A Tidy; W P Mason; D J Evans; K H Vousden
Journal:  Lancet       Date:  1992-05-02       Impact factor: 79.321

10.  Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.

Authors:  Sokbom Kang; Hy-Sook Kim; Sang Soo Seo; Sang-Yoon Park; David Sidransky; Seung Myung Dong
Journal:  Gynecol Oncol       Date:  2007-03-13       Impact factor: 5.482

View more
  314 in total

1.  Editorial on "Cancer and the microbiota" published in Science.

Authors:  Alison K Hamm; Tiffany L Weir
Journal:  Ann Transl Med       Date:  2015-08

Review 2.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 3.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

4.  Reply to Artifacts in the data of Hu et al.

Authors:  Zheng Hu; Da Zhu; Wei Wang; Weiyang Li; Wenlong Jia; Xi Zeng; Xun Xu; Hui Wang; Ding Ma
Journal:  Nat Genet       Date:  2016-01       Impact factor: 38.330

5.  Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.

Authors:  Clara Bodelon; Svetlana Vinokurova; Joshua N Sampson; Johan A den Boon; Joan L Walker; Mark A Horswill; Keegan Korthauer; Mark Schiffman; Mark E Sherman; Rosemary E Zuna; Jason Mitchell; Xijun Zhang; Joseph F Boland; Anil K Chaturvedi; S Terence Dunn; Michael A Newton; Paul Ahlquist; Sophia S Wang; Nicolas Wentzensen
Journal:  Carcinogenesis       Date:  2015-12-09       Impact factor: 4.944

6.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

7.  Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.

Authors:  Jiang-Jiang Qin; Wei Wang; Sushanta Sarkar; Ruiwen Zhang
Journal:  J Control Release       Date:  2016-07-06       Impact factor: 9.776

8.  Genetic landscape of esophageal squamous cell carcinoma.

Authors:  Yi-Bo Gao; Zhao-Li Chen; Jia-Gen Li; Xue-Da Hu; Xue-Jiao Shi; Zeng-Miao Sun; Fan Zhang; Zi-Ran Zhao; Zi-Tong Li; Zi-Yuan Liu; Yu-Da Zhao; Jian Sun; Cheng-Cheng Zhou; Ran Yao; Su-Ya Wang; Pan Wang; Nan Sun; Bai-Hua Zhang; Jing-Si Dong; Yue Yu; Mei Luo; Xiao-Li Feng; Su-Sheng Shi; Fang Zhou; Feng-Wei Tan; Bin Qiu; Ning Li; Kang Shao; Li-Jian Zhang; Lan-Jun Zhang; Qi Xue; Shu-Geng Gao; Jie He
Journal:  Nat Genet       Date:  2014-08-24       Impact factor: 38.330

9.  Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.

Authors:  Kosei Hasegawa; Masahiro Kagabu; Mika Mizuno; Katsutoshi Oda; Daisuke Aoki; Seiji Mabuchi; Shoji Kamiura; Satoshi Yamaguchi; Yoichi Aoki; Toshiaki Saito; Mayu Yunokawa; Kazuhiro Takehara; Aikou Okamoto; Kazunori Ochiai; Tadashi Kimura
Journal:  Invest New Drugs       Date:  2017-09-02       Impact factor: 3.850

10.  Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.

Authors:  Youngtae Jeong; Ngoc T Hoang; Alexander Lovejoy; Henning Stehr; Aaron M Newman; Andrew J Gentles; William Kong; Diana Truong; Shanique Martin; Aadel Chaudhuri; Diane Heiser; Li Zhou; Carmen Say; Justin N Carter; Susan M Hiniker; Billy W Loo; Robert B West; Philip Beachy; Ash A Alizadeh; Maximilian Diehn
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.